Sandu Pharmaceuticals (BOM:524703) Total Liabilities: ₹122.0 Mil (As of Mar. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

Sandu Pharmaceuticals Ltd BOM:524703

69 GF Score

Price ₹39.04

GF Value ₹58.59

Valuation Significantly Undervalued

2 Warning Signs

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

What is Sandu Pharmaceuticals Total Liabilities?

Sandu Pharmaceuticals BOM:524703 -1.16% 69 Total Liabilities is ₹122.0 Mil as of Mar. 2026. GuruFocus rates BOM:524703 with a GF Score™ of 69/100 and a GF Value™ of ₹58.59 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Sandu Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was ₹122.0 Mil.

Sandu Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2025 (₹145.84 Mil) to Dec. 2025 (₹0.00 Mil) but then increased from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹121.96 Mil).

Sandu Pharmaceuticals's annual Total Liabilities increased from Mar. 2024 (₹118.22 Mil) to Mar. 2025 (₹137.02 Mil) but then declined from Mar. 2025 (₹137.02 Mil) to Mar. 2026 (₹121.96 Mil).

Try GuruFocus Premium free for 7 days

Unlock GF Score, GF Value, 30-Y financials, and pro screeners.

Get Started →

Sandu Pharmaceuticals Total Liabilities Related Terms

Sandu Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Sandu Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sandu Pharmaceuticals Total Liabilities Chart

Sandu Pharmaceuticals Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

Total Liabilities

Get a 7-Day Free Trial

128.10

149.25

118.22

137.02

121.96

Sandu Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															137.02	0.00	145.84	0.00	121.96

69GF Score

Sandu Pharmaceuticals Ltd BOM:524703

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

Sandu Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sandu Pharmaceuticals's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	104.221	+	(3.095	+	14.644
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	122.0

Total Liabilities	=	Total Assets (A: Mar. 2026 )	-	Total Equity (A: Mar. 2026 )
	=	558.693	-	436.733
	=	122.0

Sandu Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	104.221	+	(3.095	+	14.644
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	122.0

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	558.693	-	436.733
	=	122.0

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of ₹122.0 Mil mean?

Sandu Pharmaceuticals (BOM:524703) has a Total Liabilities of ₹122.0 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sandu Pharmaceuticals and its competitors.

Is Sandu Pharmaceuticals' Total Liabilities too high?

Sandu Pharmaceuticals' current Total Liabilities is ₹122.0 Mil. Overall, Sandu Pharmaceuticals has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Sandu Pharmaceuticals' Total Liabilities compare to ZTS?

Sandu Pharmaceuticals' Total Liabilities of ₹122.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Drug Manufacturers company?

A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sandu Pharmaceuticals and its competitors. Sandu Pharmaceuticals's current Total Liabilities is ₹122.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Sandu Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Sandu Pharmaceuticals (BOM:524703) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹58.59, compared to a current price of ₹39.04 — trading 33.4% below its estimated fair value. The current Total Liabilities is ₹122.0 Mil. Sandu Pharmaceuticals' overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Sandu Pharmaceuticals (BOM:524703), the current Total Liabilities is ₹122.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sandu Pharmaceuticals (BOM:524703) Overvalued in 2026?

Based on GuruFocus' analysis, Sandu Pharmaceuticals stock appears to be undervalued. The current stock price of ₹39.04 is trading 33.4% below its estimated GF Value™ of ₹58.59. GuruFocus considers Sandu Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for BOM:524703:

Total Liabilities: ₹122.0 Mil
GF Value™: ₹58.59 vs. price of ₹39.04 (33.4% below fair value)
GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the BOM:524703 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →